Analysis reveals that antibody titer indicates potential efficacy of tumor therapy and clinical management in ROHHAD syndrome.
This study suggests that we need to evaluate clinically and in detail the autonomic dysregulation and hypoventilation in order to diagnose ROHHAD (-NET) syndrome in its early stages. Additionally, anti-ZSCAN1 antibody titers reflect the association of neural crest tumors (NCT) and may serve as a potential marker for the efficacy of tumor therapy. We also propose the anti-ZSCAN1 antibody titer as an indicator for the clinical management of ROHHAD (-NET) syndrome.
No takes yet. Share an insight, caveat, or question.
Nakamura-Utsunomiya et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: